aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Xeris Biopharma Holdings is a Chicago-based medical company focused on developing and commercializing ready-to-use, liquid-stable injectables. Utilizing novel formulation technology platforms, Xeris aims to improve treatment options for endocrine diseases and other conditions, serving a global market.
Xeris has achieved significant milestones, including the successful launch of several innovative injectable treatments. The company's impact is marked by its commitment to enhancing patient care and providing more convenient and effective therapeutic solutions.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Pharmaceuticals, Treatments
Technology
Biotech
Tags
Healthtech
Model Types
Licensing, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Healthcare
Geographic Exposure
Global
When was Xeris Biopharma Holdings founded?
Xeris Biopharma Holdings was founded in 2021.
Where is Xeris Biopharma Holdings's headquarters located?
Xeris Biopharma Holdings's headquarters is located in Chicago, IL, US.
When was Xeris Biopharma Holdings's last funding round?
Xeris Biopharma Holdings's most recent funding round was for $30M (USD) in January 2022.
How many employees does Xeris Biopharma Holdings have?
Xeris Biopharma Holdings has 355 employees as of Feb 6, 2024.
How much has Xeris Biopharma Holdings raised to-date?
As of July 05, 2023, Xeris Biopharma Holdings has raised a total of $289.7M (USD) since Jan 3, 2022.
Add Comparison
Total Raised to Date
$289.7M
USD
Last Update Jan 3, 2022
Last Deal Details
$30M
USD
Jan 3, 2022
Post Ipo Equity
Total Employees Over Time
355
As of Feb 2024
Xeris Biopharma Holdings Address
Chicago,
Illinois
60607
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts